Skip to main content Skip to section navigation Skip to footer
Investors & Media Clinical Trials Careers Contact Us
Facebook link Twitter link Linkedin link
CymaBay Therapeutics
  • Home
  • Our Company
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Purpose
    • Overview
    • About Liver Disease
    • About PBC
    • Patient Advocacy
    • Patient Resources
    • Grants & Giving
    • Expanded Access
  • Our Science
    • Overview
    • Unmet Needs in PBC
    • Seladelpar
    • MBX-2982
    • Collaborations
  • Investors & Media
  • Clinical Trials
  • Careers
  • Contact Us

Presentations

Investors & Media

Investors & Media

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Publications
    • Email Alerts
  • Company Info
    • Overview
    • Leadership Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Publications
  • Email Alerts
Sep 7, 2023

Seladelpar RESPONSE Phase 3 PBC Study Topline Results

Jun 20, 2023

Seladelpar Treatment Resulted in Correlated Decreases in Serum IL-31 and Pruritus in Patients With Primary Biliary Cholangitis (PBC): Post-hoc Results From the Phase 3 Randomized, Placebo-Controlled ENHANCE Study

Jun 20, 2023

Baseline Characteristics and Risk Profiles of 1111 Patients With Primary Biliary Cholangitis (PBC) in Need of Second-Line Therapy

Jun 20, 2023

Novel Pathways Implicated in the Seladelpar-mediated Reductions of Established Liver Fibrosis are Identified from RNAseq Data using Plex Search and Two Independent Mouse Pharmacology Datasets

Mar 23, 2023

Corporate Presentation

Nov 5, 2022

Effects of single and multiple doses of the selective PPARĪ“ agonist seladelpar on diurnal markers of bile acid synthesis in mice

Nov 5, 2022

Seladelpar, a PPAR-delta agonist, improves inflammatory lipid mediators in the serum metabolome in patients with primary biliary cholangitis (PBC)

Nov 5, 2022

Seladelpar Improved the Lipid Profile of Patients With Primary Biliary Cholangitis (PBC): Results From Phase 2 and 3 Clinical Studies

Jun 25, 2022

The selective PPAR-delta agonist seladelpar (MBX-8025) suppresses bile acid synthesis by reducing hepatocyte CYP7A1 through the FGF21 pathway

Jun 21, 2022

Comparative fibroreducing activities of selected nuclear receptor agonists in the carbon tetrachloride mouse model

rss_feed RSS
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Next Pagearrow_forward
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed
©2023 CymaBay Therapeutics. All Rights Reserved.
Privacy Policy Disclaimer Sitemap Manage Cookie Preferences
Facebook link Twitter link Linkedin link

You are leaving our website!

Continue